Browse All

Current Filters

CLEAR FILTER x

TITLE

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy

Author:Polydefkis, Michael   Aldinc, Emre   Nienhuis, Hans   Karam, Chafic   Ajroud-Driss, Senda   Sekijima, Yoshiki   Waddington-Cruz, Marcia   Barnes, Jennifer   Nioi, Paul   Ticau, Simina   

Session Name:S14: General Neurology: Emerging Therapies  

Topic:General Neurology  

Program Number:S14.001  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  Alnylam Pharmaceuticals, Cambridge, MA  Amyloidosis Centre of Expertise, University of Groningen, Groningen, Netherlands  University of Pennsylvania, Philadelphia, PA  Northwestern University Feinberg School of Medicine, Chicago, IL  Shinshu University School of Medicine, Matsumoto , Japan  CEPARM, National Amyloidosis Referral Center, University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil  

Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study

Author:Polydefkis, Michael   Birklein, Frank   Sekijima, Yoshiki   Pareyson, Davide   Waddington Cruz, Marcia   Danese, David   Capocelli, Kelley   Merkel, Madeline   Chen, Chongshu   Vest, John   Adams, David   

Session Name:S14: General Neurology: Emerging Therapies  

Topic:General Neurology  

Program Number:S14.003  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  Clinic and Polyclinic for Neurology, Johannes Gutenberg University of Mainz, Mainz, Germany  Shinshu University School of Medicine, Matsumoto, Japan  Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy  Clementino Fraga Filho University Hospital, Rio De Janeiro, Brazil  Alnylam Pharmaceuticals, Cambridge, MA  APHP, Le Kremlin-Bicetre Cedex, France